HC Wainwright Has Optimistic Outlook of DNTH Q1 Earnings

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Research analysts at HC Wainwright increased their Q1 2025 EPS estimates for shares of Dianthus Therapeutics in a research note issued on Wednesday, March 12th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($1.03) per share for the quarter, up from their previous estimate of ($1.21). HC Wainwright currently has a "Buy" rating and a $40.00 target price on the stock. The consensus estimate for Dianthus Therapeutics' current full-year earnings is ($2.61) per share. HC Wainwright also issued estimates for Dianthus Therapeutics' Q2 2025 earnings at ($1.10) EPS, Q3 2025 earnings at ($1.05) EPS, Q4 2025 earnings at ($0.89) EPS, FY2025 earnings at ($4.07) EPS and FY2026 earnings at ($4.60) EPS.

Other equities research analysts have also issued reports about the stock. Guggenheim reiterated a "buy" rating and set a $84.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Raymond James upgraded shares of Dianthus Therapeutics to a "moderate buy" rating in a report on Thursday, December 12th. Wedbush restated an "outperform" rating and issued a $36.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, TD Cowen assumed coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They issued a "buy" rating on the stock. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $52.14.

Remove Ads

Dianthus Therapeutics Price Performance

Shares of DNTH stock remained flat at $20.59 during trading hours on Monday. 73,419 shares of the stock traded hands, compared to its average volume of 237,227. The firm has a market capitalization of $609.40 million, a PE ratio of -8.25 and a beta of 1.82. Dianthus Therapeutics has a 52-week low of $18.13 and a 52-week high of $33.77. The business's fifty day moving average is $22.24 and its two-hundred day moving average is $24.67.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The firm had revenue of $1.33 million for the quarter, compared to analyst estimates of $1.40 million.

Institutional Trading of Dianthus Therapeutics

Several hedge funds have recently made changes to their positions in DNTH. R Squared Ltd acquired a new stake in shares of Dianthus Therapeutics in the 4th quarter worth $26,000. Quest Partners LLC lifted its stake in shares of Dianthus Therapeutics by 112,400.0% in the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company's stock worth $31,000 after acquiring an additional 1,124 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in shares of Dianthus Therapeutics in the 4th quarter worth $33,000. KBC Group NV acquired a new stake in shares of Dianthus Therapeutics in the 4th quarter worth $35,000. Finally, BNP Paribas Financial Markets acquired a new stake in shares of Dianthus Therapeutics in the 4th quarter worth $59,000. Institutional investors and hedge funds own 47.53% of the company's stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.